Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 74 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 74 samples: 74 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE301719_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1287461 and SRA study SRP598564. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 74 sample titles: 74 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9087673 Tact1,DMSO (ATAC)
- GSM9087674 Tact2,DMSO (ATAC)
- GSM9087675 Tact3,DMSO (ATAC)
- GSM9087676 Tex1,Mezi (ATAC)
- GSM9087677 Tex1,DMSO (ATAC)
- GSM9087678 Tex2,Mezi (ATAC)
- GSM9087679 Tex2,DMSO (ATAC)
- GSM9087680 Tex3,Mezi (ATAC)
- GSM9087681 Tex3,DMSO (ATAC)
- GSM9087682 MM1 Tact DMSO (scATACseq)
- GSM9087683 MM1 Tact Mezi (scATACseq)
- GSM9087684 MM2 Tact DMSO (scATACseq)
- GSM9087685 MM2 Tact Mezi (scATACseq)
- GSM9087686 MM11 Tact DMSO (scATACseq)
- GSM9087687 MM11 Tact Mezi (scATACseq)
- GSM9087688 MM12 Tact DMSO (scATACseq)
- GSM9087689 MM12 Tact Mezi (scATACseq)
- GSM9087690 INPUT
- GSM9087691 Tact1,DMSO,Ikaros (ChIP)
- GSM9087692 Tact2,DMSO,Ikaros (ChIP)
- GSM9087693 Tact3,DMSO,Ikaros (ChIP)
- GSM9087694 Tact1,DMSO,H3K27Ac (ChIP)
- GSM9087695 Tact2,DMSO,H3K27Ac (ChIP)
- GSM9087696 Tact3,DMSO,H3K27Ac (ChIP)
- GSM9087697 Tact1,DMSO,H3K4me1 (ChIP)
- GSM9087698 Tact2,DMSO,H3K4me1 (ChIP)
- GSM9087699 Tact3,DMSO,H3K4me1 (ChIP)
- GSM9087700 Tact1,DMSO,H3K4me3 (ChIP)
- GSM9087701 Tact2,DMSO,H3K4me3 (ChIP)
- GSM9087702 Tact3,DMSO,H3K4me3 (ChIP)
- GSM9087703 Tex1,Mezi,Ikaros (ChIP)
- GSM9087704 Tex1,DMSO,Ikaros (ChIP)
- GSM9087705 Tex2,Mezi,Ikaros (ChIP)
- GSM9087706 Tex2,DMSO,Ikaros (ChIP)
- GSM9087707 Tex3,DMSO,Ikaros (ChIP)
- GSM9087708 Tex3,Mezi,Ikaros (ChIP)
- GSM9087709 Tex1,Mezi,H3K27Ac (ChIP)
- GSM9087710 Tex1,DMSO,H3K27Ac (ChIP)
- GSM9087711 Tex2,Mezi,H3K27Ac (ChIP)
- GSM9087712 Tex2,DMSO,H3K27Ac (ChIP)
+ 34 more — browse all 74 samples with per-sample file links →
- GSE301715 Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [ChIP-seq] 37 samples shares reinvigoration, mezigdomide, degradation, exhaustion, production, reverses, cytokine, aiolos
- GSE301716 Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [RNA-seq] 9 samples shares reinvigoration, mezigdomide, degradation, exhaustion, production, reverses, cytokine, aiolos
- GSE301713 Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [ATAC-seq] 9 samples shares reinvigoration, mezigdomide, degradation, exhaustion, production, reverses, cytokine, aiolos
- GSE301714 Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [scATAC-seq] 8 samples shares reinvigoration, mezigdomide, degradation, exhaustion, production, reverses, cytokine, aiolos
- GSE301717 Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [scRNA-seq] 8 samples shares reinvigoration, mezigdomide, degradation, exhaustion, production, reverses, cytokine, aiolos
- GSE301718 Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [Hi-C] 3 samples shares reinvigoration, mezigdomide, degradation, exhaustion, production, reverses, cytokine, aiolos
- GSE266052 Cytokine Priming Enhances the Antifibrotic Effects of Mesenchymal Stromal Cells Conditioned Medium Via Fibrogenic Myofibroblasts Elimination and Extracellular Matrix Degradation. 20 samples shares degradation, cytokine
- GSE244184 Degradation of Ikaros prevents epigenetic progression of T cell exhaustion in novel antigen-specific assay 15 samples shares degradation, exhaustion
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.